The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real ...

Spanish pharma Grifols is leveraging its massive collection ... “The hope is to accelerate and ultimately develop new diagnostics and disease-modifying therapeutics that could mitigate or ...

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes ...

BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF ... “Chronos-PD,” could accelerate the discovery of new diagnostic tools as well as the identification and development ...

Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael ... The initiative, named Chronos-PD, could lead to the discovery of new ...